Welcome to our dedicated page for National Resh SEC filings (Ticker: NRC), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NRC Health SEC filings document an operating company that provides healthcare experience improvement and healthcare experience management solutions under the NRC ticker on Nasdaq. Its current filings include 8-K reports for quarterly financial and operating results, Regulation FD updates on Total Recurring Contract Value, and exhibits containing company press releases.
The filing record also covers governance and capital-structure matters, including the completed corporate name change from National Research Corporation to NRC Health, charter and bylaw amendments, board declassification, executive officer appointments and compensation arrangements, equity award terms, proxy disclosures, director elections, executive compensation, and common-stock matters.
NRC Health reported results of its 2026 annual stockholder meeting and subsequent governance changes. Stockholders approved amendments to the company’s certificate of incorporation, and an Amended and Restated Certificate of Incorporation became effective on June 24, 2026.
The board also amended the bylaws on June 23, 2026 to align written-consent voting requirements with the new charter, effective upon the charter’s effectiveness. Directors received strong support, with individual nominees generally receiving about 19.8 million votes in favor versus materially smaller totals against, alongside broker non-votes.
Berwick Donald M reported acquisition or exercise transactions in this Form 4 filing.
NRC HEALTH director Donald M. Berwick received an equity grant as part of his annual board compensation. He was awarded 7,697 shares of common stock at a price of $0.00 per share, bringing his directly held stake to 7,697 shares after the transaction.
The footnote explains this represents $150,000 of annual equity compensation in the form of restricted stock units under the company’s 2025 Omnibus Incentive Plan, calculated using the closing price before the 2026 annual stockholders’ meeting. The award will vest on the date of the 2027 annual stockholder meeting, subject to standard vesting, forfeiture, and termination provisions.
Bhandari Parul reported acquisition or exercise transactions in this Form 4 filing.
NRC HEALTH director Parul Bhandari reported an equity grant of 7,697 shares of Common Stock as annual compensation. The award represents restricted stock units valued at $150,000, calculated using the closing price on the day before NRC HEALTH’s 2026 annual stockholder meeting.
The grant was made under the company’s 2025 Omnibus Incentive Plan at a stated price of $0.0000 per share, reflecting that this is a compensation award rather than an open-market purchase. All 7,697 shares will vest and become exercisable on the date of the company’s 2027 annual stockholder meeting, subject to standard vesting, forfeiture, and termination conditions.
Lockhart Stephen H reported acquisition or exercise transactions in this Form 4 filing.
NRC Health director Stephen H. Lockhart reported receiving an equity grant of 7,697 shares of common stock as annual compensation. According to the disclosure, this grant represents restricted stock units valued at $150,000, determined using the closing share price before the company’s 2026 annual stockholders meeting.
The award was granted under NRC Health’s 2025 Omnibus Incentive Plan and will vest and become exercisable on the date of the company’s 2027 annual stockholder meeting, subject to standard vesting, forfeiture, and termination provisions. Following this award, Lockhart directly holds 7,697 shares.
NUNNELLY JOHN N reported acquisition or exercise transactions in this Form 4 filing.
NRC HEALTH director John N. Nunnelly received an equity award of 7,697 restricted stock units of Common Stock as annual compensation. The grant represents $150,000 of value, calculated using the closing share price before the company’s 2026 annual stockholder meeting. After this award, he holds 40,363 shares directly. The restricted stock units will vest and become exercisable on the date of the company’s 2027 annual stockholder meeting, subject to standard vesting, forfeiture, and termination conditions.
Wheeler Penny Ann reported acquisition or exercise transactions in this Form 4 filing.
NRC Health director Penny Ann Wheeler reported receiving an annual equity grant of 7,697 shares of common stock as restricted stock units valued at $150,000. The award represents annual equity compensation under NRC Health’s 2025 Omnibus Incentive Plan and was granted at no cash cost to her. These units will vest and become exercisable on the date of the company’s 2027 annual stockholder meeting, subject to standard vesting, forfeiture, and termination conditions, leaving her with 7,697 shares reported as directly owned after the grant.
NRC Health’s major shareholders updated their Schedule 13D to reflect current holdings and recent trades. Common Property Trust reports beneficial ownership of 8,609,601 shares of Common Stock, or 38.2% of the class, based on 22,536,696 shares outstanding as of April 30, 2026. Amandla LLC holds 4,755,317 shares (21.1%), and Common Property Trust LLC holds 3,854,284 shares (17.1%). Patrick E. Beans is deemed to beneficially own 10,305,634 shares, representing 45.7% of the company, while founder and Chairman Michael D. Hays reports 597,299 shares, or 2.7%, and states that, excluding specified excluded shares, he ceased to be a beneficial owner of more than five percent as of March 23, 2026. The filing also notes that on June 10, 2026, one of the irrevocable trusts sold 224,457 shares at a weighted average price of $20.02 per share and 25,543 shares at a weighted average price of $21.05 per share, and that a charitable foundation formed by Hays gifted 20,000 shares on April 21, 2026.
NRC Health is registering 14,524,566 shares of Common Stock for resale by selling shareholders under Prospectus Supplement No. 3 dated May 13, 2026.
The supplement updates the Selling Shareholders table to reflect estate planning transactions and prior sales and lists per‑holder quantities. Shares outstanding were 22,536,696 as of April 30, 2026.
NRC Health is asking stockholders to vote at its virtual annual meeting on June 23, 2026 to elect seven directors, ratify KPMG LLP as auditor for 2026, and approve a non-binding say‑on‑pay resolution for its named executive officers.
Stockholders are also asked to approve three charter amendments: removing certain supermajority voting requirements, eliminating restrictions on removing directors only for cause, and reducing the stockholder written‑consent threshold from unanimity to the voting power needed if the action were taken at a meeting. The proxy details 2025 leadership transitions, including Trent Green becoming CEO, and discloses 2025 CEO pay of $11.96 million, a CEO pay ratio of 165:1, and significant equity and cash awards tied to refreshed strategy and leadership changes.